Lung Cancer | Specialty

FDA Approval Insights: Lurbinectedin in Metastatic SCLC

September 24th 2020

In our exclusive interview, Jacob Sands, MD, discusses the FDA approval of lurbinectedin in small cell lung cancer and shed light on key findings from the phase 2 basket trial that served as the basis for the approval.

Experts Call for Increased Awareness of Existing Racial Disparities in RCC, Other Malignancies

September 24th 2020

Despite the numerous reports detailing racial differences in cancer outcomes and care over the years, the reasons underlying these disparities continue to be under deep exploration.

Cemiplimab Demonstrates Frontline Potential in Advanced PD-L1+ NSCLC

September 21st 2020

Cemiplimab-rwlc monotherapy led to a significant improvement in overall survival and progression-free survival versus platinum-doublet chemotherapy as first-line therapy in patients with advanced non–small cell lung cancer with PD-L1 expression on at least 50% of their tumor cell.

Durvalumab/Tremelimumab Shows Modest Activity in Advanced NETs With GEP and Lung Origins

September 21st 2020

The addition of durvalumab to tremelimumab showed modest activity in patients with advanced neuroendocrine tumors of gastroenteropancreatic and lung origins.

Osimertinib Improves CNS Disease-Free Survival in Early EGFRm NSCLC

September 21st 2020

Osimertinib reduced the risk for central nervous system death or progression by 82% in patients with early-stage EGFR mutated non–small cell lung cancer following complete tumor resection.

BLU-945 Elicits Robust Clinical Activity in Preclinical EGFR+ Lung Cancer Models

September 20th 2020

BLU-945, an investigational precision therapy, elicited robust antitumor activity in multiple preclinical models of triple-mutated EGFR-positive non–small cell lung cancer .

EGFR-MET Bispecific Antibody Amivantamab Excels in Advanced EGFR-Mutant NSCLC

September 20th 2020

The combination of amivantamab and lazertinib demonstrated high response rates and was well tolerated in treatment-naïve and osimertinib-resistant patients with advanced EGFR-mutant non–small cell lung cancer.

First-Line Apatinib/Gefitinib Combo Shows Significant Benefit for EGFR-Mutant NSCLC

September 20th 2020

Dual inhibition of both VEGFR and EGFR with the combination of apatinib and gefitinib in the first-line treatment of patients with advanced EGFR-mutant non–small cell lung cancer demonstrated superior progression-free survival.

Osimertinib/Bevacizumab Combination Fails to Prolong PFS in EGFR T790M+ Lung Cancer

September 20th 2020

The combination of osimertinib and bevacizumab did not prolong progression-free survival in patients with advanced adenocarcinoma who had EGFR T790M mutations compared with osimertinib alone

Sotorasib Shows Encouraging Antitumor Activity in Advanced NSCLC

September 20th 2020

The investigational drug sotorasib demonstrated promising antitumor activity in patients with non-small cell lung cancer that harbor the KRAS p.G12C mutation, an aberration for which no targeted treatment has yet been approved.

PORT Not Recommended as Standard of Care in Completely Resected Stage IIIAN2 NSCLC

September 20th 2020

Post-operative radiotherapy was linked with a nonstatistically significant increase in disease-free survival in patients with completely resected stage IIIAN2 non–small cell lung cancer and thus cannot be recommended as a standard of care for this population.

Dr. Solomon on the Results of the Phase 3 CROWN Study in ALK-Positive NSCLC

September 20th 2020

Benjamin Solomon, MBBS, PhD, FRACP, discusses interim findings from the phase 3 CROWN study in ALK-positive non–small cell lung cancer.

Frontline Lorlatinib Bests Crizotinib in Advanced ALK+ NSCLC

September 20th 2020

First-line treatment with the third-generation ALK TKI lorlatinib significantly improved progression-free survival, and also was associated with higher overall and intracranial response rates, compared with crizotinib in patients with ALK-positive non–small cell lung cancer.

Neoadjuvant Durvalumab Induces Responses in Resectable NSCLC, But High Postsurgical Mortality Ends Study

September 19th 2020

Neoadjuvant durvalumab achieved a satisfactory complete surgical resection rate in patients with resectable non–small cell lung cancer, demonstrating preliminary promise for this treatment strategy.

Tumor Regression Is Observed With Neoadjuvant Atezolizumab in Resectable NSCLC

September 19th 2020

One preoperative injection of atezolizumab was considered safe and induced major pathological responses in select patients with resectable non–small cell lung cancer.

EMA Recommends Approval of Nivolumab/Ipilimumab Plus Chemo in Frontline Metastatic NSCLC

September 18th 2020

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended the approval of nivolumab plus ipilimumab with 2 cycles of platinum-based chemotherapy for the frontline treatment of patients with metastatic non–small cell lung cancer.

Nivolumab/Ipilimumab Takes Step Toward EU Approval in Frontline Malignant Pleural Mesothelioma

September 17th 2020

The European Medicines Agency has validated a Type II Variation for nivolumab in combination with ipilimumab as a frontline treatment for previously untreated patients with unresectable malignant pleural mesothelioma.

Reducing the Impact of Chemotherapy-Induced Myelosuppression

September 16th 2020

CDK4/6 Inhibitors & Myelopreservation in Other Cancers

September 16th 2020

CDK4/6 Inhibitors for SCLC: Trials of Interest

September 16th 2020